Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Oritavancin (Orbactiv / Kimyrsa) Peptide
Single-dose lipoglycopeptide for acute bacterial skin and skin structure infections.
What is Oritavancin (Orbactiv / Kimyrsa)?
Oritavancin (Orbactiv / Kimyrsa) is a lipoglycopeptide · antibiotic peptide studied for acute bacterial skin and skin structure infections (absssi). Below is an educational overview of Oritavancin (Orbactiv / Kimyrsa) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Orbactiv, Kimyrsa
Acute bacterial skin and skin structure infections (ABSSSI), including MRSA.
A single IV dose that treats serious skin infections — no need for daily IV antibiotics afterward.
- •Headache
- •Nausea
- •Vomiting
- •Limb/subcutaneous abscess
- •Diarrhea
- •Falsely elevated coagulation tests (aPTT/PT) up to 48 hours
- •Avoid IV unfractionated heparin for 48 hours
- •Hypersensitivity reactions
- •C. difficile colitis
- •IV unfractionated heparin needed within 48 hours of dose
- •Known hypersensitivity to glycopeptides
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Oritavancin (Orbactiv / Kimyrsa) Mechanism of Action
Semisynthetic lipoglycopeptide derivative of chloroeremomycin that inhibits cell wall synthesis (transglycosylation, transpeptidation) and disrupts membrane integrity in Gram-positive bacteria including MRSA.
Oritavancin (Orbactiv / Kimyrsa) Research Areas & Benefits
Oritavancin (Orbactiv / Kimyrsa) Dosage & Common Research Protocols
1200 mg IV over 1–3 hours as a single dose.
Protocols summarized for educational reference from published research. Not dosing guidance.
Oritavancin (Orbactiv / Kimyrsa) Studies & Cited Research
SOLO trials
Single dose non-inferior to 7–10 days of vancomycin in ABSSSI.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Oritavancin (Orbactiv / Kimyrsa) Side Effects & Safety Considerations
- •FDA-approved.
- •Artifactually elevates aPTT/PT for up to 48 hours; avoid unfractionated heparin for 48h.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.